Advertisement
UK markets close in 3 hours 21 minutes

  • FTSE 100

    8,118.24
    +39.38 (+0.49%)
     

  • FTSE 250

    19,810.01
    +208.03 (+1.06%)
     

  • AIM

    754.89
    +1.77 (+0.24%)
     

  • GBP/EUR

    1.1675
    +0.0019 (+0.16%)
     

  • GBP/USD

    1.2511
    -0.0000 (-0.00%)
     

  • Bitcoin GBP

    51,391.94
    +424.61 (+0.83%)
     

  • CMC Crypto 200

    1,385.98
    -10.56 (-0.76%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • CRUDE OIL

    84.14
    +0.57 (+0.68%)
     

  • GOLD FUTURES

    2,357.00
    +14.50 (+0.62%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     

  • DAX

    18,052.76
    +135.48 (+0.76%)
     

  • CAC 40

    8,045.36
    +28.71 (+0.36%)
     
PROPERTY:

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

NetScientific's unit signs deal to sell AstraZeneca's COVID-19 test

Reuters
·1-min read
FILE PHOTO: Test tubes are seen in front of a displayed AstraZeneca logo in this illustration

(Reuters) - British life sciences company NetScientific Plc said on Monday that one of its subsidiaries has entered an exclusive licensing agreement with AstraZeneca Plc to globally sell a COVID-19 test.

NetScientific's wholly-owned unit ProAxsis Ltd will look after completing validation and global commercialisation of AstraZeneca's SARS-CoV-2 serology ELISA and, in return, the Anglo-Swedish drugmaker will receive a royalty fee on future global net sales of the assay, the company said.

The ELISA, or enzyme-linked immunosorbent assay that is developed by an internal research team at AstraZeneca, is a highly sensitive and specific blood test that collects samples from a finger prick. AstraZeneca said the test will be well-suited for antibody analyses in large populations.

"The assay could, if fully validated, potentially attract a substantial market," NetScientific Chief Executive Officer Ilian Iliev said in a statement.

NetScientific holds 95% stake in ProAxsis on a fully diluted basis.

(Reporting by Vishwadha Chander in Bengaluru; editing by Uttaresh.V)